Literature DB >> 25665485

The effects of estrogen on serum level and hepatocyte expression of PCSK9.

Wen Guo1, Jinxiang Fu2, Xiaoli Chen2, Beibei Gao2, Zhenzhen Fu2, Hongqi Fan2, Qin Cui3, Xiaohui Zhu2, Yang Zhao4, Tao Yang2, Daping Fan5, Hongwen Zhou6.   

Abstract

OBJECTIVE: We previously reported that serum PCSK9 levels are higher in postmenopausal women than in premenopausal women in a Han Chinese population. Whether this difference is related to estrogen has not been well-characterized. This study aims to examine if the alteration in estrogen level is responsible for the changes of serum PCSK9 concentration. MATERIALS/
METHODS: A sandwich ELISA assay was used to measure serum PCSK9 levels in 727 healthy women aged from 26 to 85 years old. Anthropometric and biochemical examination of parameters such as estrogen and serum lipids was also performed for these individuals. Next, we measured serum PCSK9 and estrogen levels of 30 healthy fertile women (24-26 years old) in their menstrual cycles and analyzed the correlation between serum PCSK9 level and estrogen concentration. Moreover, cell culture studies were carried out to examine if estrogen at physiological and non-physiological concentrations regulates hepatocyte PCSK9 expression.
RESULTS: Serum PCSK9 concentrations were significantly increased with aging. Aged group had higher serum PCSK9 levels than the middle aged group and the young group (60.29±28.47 vs 71.38±34.22 vs 83.81±33.50 ng/ml). Serum PCSK9 levels were positively correlated with age, BMI, serum total cholesterol and LDL-cholesterol (P<0.01), but not correlated with estrogen levels. There was no significantly difference of PCSK9 levels between the lower and the upper estradiol (E2) tertiles in the 727 women. There was either no significant difference in PCSK9 levels during the menstrual, ovulatory, luteal phases in the 30 healthy fertile women. Cell culture studies showed that 17β-estradiol at physiological concentrations did not significantly alter PCSK9 expression in human hepatocytes.
CONCLUSION: The serum PCSK9 levels were higher in postmenopausal women than those in pre-menopausal women. However, the difference in serum PCSK9 levels between postmenopausal and premenopausal woman appeared to be independent of estrogen status, and estrogen at physiological concentrations does not affect human hepatocyte PCSK9 expression.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Estrogen; Low-density lipoprotein cholesterol (LDL-C); Low-density lipoprotein receptor (LDLR); Proprotein convertase subtilisin/kexin type 9 (PCSK9)

Mesh:

Substances:

Year:  2015        PMID: 25665485     DOI: 10.1016/j.metabol.2015.01.009

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  6 in total

1.  Obesity and type 2 diabetes are associated with elevated PCSK9 levels in young women.

Authors:  Amy E Levenson; Amy S Shah; Philip R Khoury; Thomas R Kimball; Elaine M Urbina; Sarah D de Ferranti; David M Maahs; Lawrence M Dolan; R Paul Wadwa; Sudha B Biddinger
Journal:  Pediatr Diabetes       Date:  2017-01-17       Impact factor: 4.866

2.  17β-estradiol lowers triglycerides in adipocytes via estrogen receptor α and it may be attenuated by inflammation.

Authors:  Fei Luo; Wen-Yu Huang; Yuan Guo; Gui-Yun Ruan; Ran Peng; Xiang-Ping Li
Journal:  Lipids Health Dis       Date:  2017-09-25       Impact factor: 3.876

3.  Estrogen lowers triglyceride via regulating hepatic APOA5 expression.

Authors:  Fei Luo; Yuan Guo; Gui-Yun Ruan; Ran Peng; Xiang-Ping Li
Journal:  Lipids Health Dis       Date:  2017-04-04       Impact factor: 3.876

4.  Association of circulating proprotein convertase subtilisin/kexin type 9 levels and the risk of incident type 2 diabetes in subjects with prediabetes: a population-based cohort study.

Authors:  Jie Shi; Weiwei Zhang; Yixin Niu; Ning Lin; Xiaoyong Li; Hongmei Zhang; Renming Hu; Guang Ning; Jiangao Fan; Li Qin; Qing Su; Zhen Yang
Journal:  Cardiovasc Diabetol       Date:  2020-12-10       Impact factor: 9.951

5.  Association of the variants and haplotypes in the DOCK7, PCSK9 and GALNT2 genes and the risk of hyperlipidaemia.

Authors:  Tao Guo; Rui-Xing Yin; Wei-Xiong Lin; Wei Wang; Feng Huang; Shang-Ling Pan
Journal:  J Cell Mol Med       Date:  2015-10-23       Impact factor: 5.310

6.  Circulating Proprotein Convertase Subtilisin/Kexin Type 9 Levels and Cardiometabolic Risk Factors: A Population-Based Cohort Study.

Authors:  Jie Shi; Xiaoyong Li; Weiwei Zhang; Yixin Niu; Ning Lin; Hongmei Zhang; Guang Ning; Jiangao Fan; Li Qin; Qing Su; Zhen Yang
Journal:  Front Cardiovasc Med       Date:  2021-05-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.